Company Description
Acura Pharmaceuticals, Inc., an innovative drug delivery company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States.
It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products.
Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc. and Egalet Ltd. to manufacture and commercialize Oxaydo products worldwide; and development and commercialization agreement with Abuse Deterrent Pharma, LLC to develop LTX-03, an immediate-release tablets utilizing LIMITx technology.
The company was formerly known as Halsey Drug Co., Inc. The company was incorporated in 1935 and is based in Palatine, Illinois.
Acura Pharmaceuticals, Inc. operates as a subsidiary of Abuse Deterrent Pharma, LLC.
| Country | United States |
| Founded | 1935 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 9 |
| CEO | Robert B. Jones |
Contact Details
Address: 616 N. North Court, Suite 120 Palatine, Illinois 60067 United States | |
| Phone | 847-705-7709 |
| Website | acurapharm.com |
Stock Details
| Ticker Symbol | ACUR |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000786947 |
| CUSIP Number | 00509L802 |
| ISIN Number | US00509L8028 |
| Employer ID | 11-0853640 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Robert B. Jones | Chief Executive Officer, President and Director |
| Peter A. Clemens | Senior Vice President, Chief Financial Officer and Secretary |
| Robert A. Seiser CPA, Ph.D. | Vice President, Treasurer and Corporate Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 1, 2024 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Mar 26, 2024 | 8-K | Current Report |
| Mar 18, 2024 | 8-K | Current Report |
| Feb 14, 2024 | 8-K | Current Report |
| Feb 2, 2024 | 8-K | Current Report |
| Jan 10, 2024 | 8-K | Current Report |
| Dec 21, 2023 | 8-K | Current Report |
| Dec 6, 2023 | 8-K | Current Report |
| Nov 3, 2023 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| Oct 12, 2023 | 8-K | Current Report |